Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Croda International is a UK-based specialty chemicals manufacturer focused on high-value ingredients for personal care, life sciences, and performance technologies. The company operates 13 manufacturing sites globally with particular strength in sustainable bio-based surfactants, excipients for pharmaceutical formulations, and crop protection adjuvants. Recent performance reflects margin compression from destocking cycles in personal care end-markets and elevated raw material costs, though the 45% gross margin demonstrates pricing power in specialized formulations.
Croda generates returns through proprietary formulation chemistry and application expertise rather than commodity-scale production. The company commands premium pricing (45% gross margins vs 25-30% for commodity chemicals) by solving specific technical problems for customers - developing stable vaccine adjuvants, creating sustainable palm-oil alternatives, or formulating high-performance lubricants. Revenue is typically contracted with 6-12 month pricing agreements tied to raw material indices plus value-added premiums. The Life Sciences segment provides counter-cyclical stability with multi-year pharmaceutical development partnerships, while Personal Care is more volatile but benefits from premiumization trends in skincare.
Personal care destocking cycles and beauty market demand trends, particularly in prestige skincare categories in China and North America
Life Sciences contract wins for vaccine adjuvants and pharmaceutical excipients, which provide multi-year revenue visibility
Raw material cost inflation (palm oil derivatives, ethylene oxide, specialty oils) and ability to pass through pricing
Sustainability-driven product mix shift toward bio-based alternatives commanding 10-15% price premiums
Currency translation effects given 60%+ revenue outside UK and GBP-denominated cost base
Sustainability regulations accelerating shift away from palm oil derivatives (40-50% of raw material base) faster than bio-based alternatives can scale economically, compressing margins during transition
Pharmaceutical customer vertical integration into excipient manufacturing to reduce supply chain dependencies post-COVID, particularly for high-volume generic drug ingredients
Synthetic biology and fermentation technologies enabling competitors to produce specialty molecules at lower cost than traditional oleochemical processes
Larger diversified chemical companies (BASF, Evonik, Clariant) expanding specialty portfolios through M&A, bringing greater R&D resources and customer cross-selling capabilities
Asian specialty chemical manufacturers moving up value chain with improving technical capabilities and 20-30% cost advantages in personal care ingredients
Customer concentration risk with top 10 customers representing estimated 30-35% of revenue, providing negotiating leverage during contract renewals
Pension obligations in UK defined benefit schemes creating volatility in comprehensive income and potential cash funding requirements if discount rates decline
Working capital intensity (estimated 20-25% of sales) vulnerable to rapid volume declines, as seen in recent destocking cycle reducing operating cash flow to $0.3B
Currency mismatch with significant USD and EUR revenue but GBP cost base creates translation and transaction exposure, though partially hedged
moderate - Life Sciences (40-45% of revenue) provides defensive characteristics with pharmaceutical and agricultural demand relatively GDP-insensitive. Personal Care exhibits cyclical sensitivity to discretionary spending on premium beauty products, particularly vulnerable during consumer confidence downturns. Performance Technologies correlates with industrial production and automotive manufacturing. Overall, the portfolio balances defensive and cyclical exposures, with recent -3.9% revenue decline reflecting destocking rather than end-demand collapse.
Rising rates create modest headwinds through higher financing costs on the £1.1B net debt position (0.33 D/E implies approximately £1.1B debt vs £3.3B equity at $5.8B market cap). More significantly, rate increases pressure valuation multiples for quality compounders trading at 13.3x EV/EBITDA. Demand impact is limited as B2B customers' purchasing decisions are driven by formulation requirements rather than financing availability. The 2.07x current ratio provides liquidity buffer against refinancing risk.
Minimal direct exposure - customers are primarily investment-grade multinational corporations in pharmaceuticals and consumer goods. Payment terms are standard 30-60 days with limited bad debt historically. The company's own credit profile (0.33 D/E, 2.07x current ratio) is strong, providing flexibility for bolt-on M&A in specialty ingredients.
value - The stock attracts quality-focused value investors seeking defensive specialty chemical exposure with 45% gross margins and strong ROIC characteristics, currently trading at depressed 13.3x EV/EBITDA (below historical 15-18x range) due to cyclical Personal Care weakness. The 2.4% FCF yield and modest 6.2% ROE reflect temporary margin compression rather than structural deterioration. Recent 22.7% six-month return suggests early-stage recovery positioning as destocking cycle bottoms.
moderate - Specialty chemicals exhibit lower volatility than commodity chemicals due to contracted pricing and technical customer relationships, but Personal Care exposure creates earnings variability. Estimated beta of 0.9-1.1 reflects correlation with European industrials and consumer discretionary sectors. Currency translation adds 5-10% earnings volatility annually.
